- Home
- ESP vs ZNTL Comparison
ESP vs ZNTL Comparison
Compare ESP & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESP
- ZNTL
- Stock Information
- Founded
- ESP 1928
- ZNTL 2014
- Country
- ESP United States
- ZNTL United States
- Employees
- ESP N/A
- ZNTL N/A
- Industry
- ESP Industrial Machinery/Components
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ESP Technology
- ZNTL Health Care
- Exchange
- ESP Nasdaq
- ZNTL Nasdaq
- Market Cap
- ESP 131.5M
- ZNTL 105.8M
- IPO Year
- ESP N/A
- ZNTL 2020
- Fundamental
- Price
- ESP $52.30
- ZNTL $1.49
- Analyst Decision
- ESP
- ZNTL Buy
- Analyst Count
- ESP 0
- ZNTL 7
- Target Price
- ESP N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- ESP 23.4K
- ZNTL 805.4K
- Earning Date
- ESP 11-12-2025
- ZNTL 11-11-2025
- Dividend Yield
- ESP 1.93%
- ZNTL N/A
- EPS Growth
- ESP 39.20
- ZNTL N/A
- EPS
- ESP 2.67
- ZNTL N/A
- Revenue
- ESP $45,965,588.00
- ZNTL $26,865,000.00
- Revenue This Year
- ESP N/A
- ZNTL N/A
- Revenue Next Year
- ESP N/A
- ZNTL N/A
- P/E Ratio
- ESP $18.63
- ZNTL N/A
- Revenue Growth
- ESP 29.60
- ZNTL N/A
- 52 Week Low
- ESP $22.50
- ZNTL $1.01
- 52 Week High
- ESP $52.68
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- ESP 64.95
- ZNTL 43.18
- Support Level
- ESP $46.00
- ZNTL $1.60
- Resistance Level
- ESP $51.75
- ZNTL $2.02
- Average True Range (ATR)
- ESP 2.14
- ZNTL 0.13
- MACD
- ESP 0.48
- ZNTL -0.04
- Stochastic Oscillator
- ESP 97.34
- ZNTL 5.36
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.